ERBB2 and neoplasm: While monoclonal antibodies and TKIs impede HER2-positive tumor proliferation by blocking the HER2 signaling pathway, mutations in PIK3CA, absence of PTEN, and alternative signaling pathways may reduce TKI efficacy (24, 25).